Back to Search
Start Over
An mRNA vaccine encoding the SARS-CoV-2 receptor-binding domain protects mice from various Omicron variants.
- Source :
- NPJ Vaccines; 1/2/2024, Vol. 9 Issue 1, p1-10, 10p
- Publication Year :
- 2024
-
Abstract
- Here, we assessed the efficacy of a lipid nanoparticle-based mRNA vaccine candidate encoding the receptor-binding domain (LNP-mRNA-RBD) in mice. Mice immunized with LNP-mRNA-RBD based on the ancestral strain (ancestral-type LNP-mRNA-RBD) showed similar cellular responses against the ancestral strain and BA.5, but their neutralizing activity against BA.5 was lower than that against the ancestral strain. The ancestral-type LNP-mRNA-RBD protected mice from the ancestral strain or BA.5 challenge; however, its ability to reduce the viral burdens after BA.5 challenge was limited. In contrast, immunization with bivalent LNP-mRNA-RBD consisting of the ancestral-type and BA.4/5-type LNP-mRNA-RBD or monovalent BA.4/5-type LNP-mRNA-RBD elicited robust cellular responses, as well as high and moderate neutralizing titers against BA.5 and XBB.1.5, respectively. Furthermore, the vaccines containing BA.4/5-type LNP-mRNA-RBD remarkably reduced the viral burdens following BA.5 or XBB.1.5 challenge. Overall, our findings suggest that LNP-mRNA-RBD is effective against SARS-CoV-2 infection. [ABSTRACT FROM AUTHOR]
- Subjects :
- SARS-CoV-2 Omicron variant
COVID-19 vaccines
MICE
SARS-CoV-2
Subjects
Details
- Language :
- English
- ISSN :
- 20590105
- Volume :
- 9
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- NPJ Vaccines
- Publication Type :
- Academic Journal
- Accession number :
- 174581017
- Full Text :
- https://doi.org/10.1038/s41541-023-00800-0